Evalstotug

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Evalstotug
www.ebi.ac.uk

  • ba 3071
  • BA-3071
  • ba3071
  • Ba3071
  • BA3071
  • evalstotug
  • Evalstotug
  • Evalstotug (BA3071)
  • evalstotug [INN]
  • Evalstotug [WHO-DD]
  • evalstotug ba3071
  • evalstotug inn
  • evalstotug who dd
  • Gamma1 heavy chain (1-447) [VH (Homo sapiens IGHV3-30*02 (91.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12, L14 (CH1 R120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359)(342-446), CHS K2>del (447)) (119-447)], (221-215')-disulfide with kappa light chain (1'-215') [V-KAPPA (Homo sapiens IGKV1-9*03 (78.1%) -IGKJ1*01 (100%), CDR-IMGT [7.3.9] (27'-33'.51'-53'.90'-98')) (1'-108') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (154'), V101 (192') (109'-215')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, glycoform alfa
  • gamma1 heavy chain 1 447 vh homo sapiens ighv3 30 02 91 8 ighd ighj4 01 100 cdr imgt 8 8 11 26 33 51 58 97 107 1 118 homo sapiens ighg1 01 100 g1m17 1 ch1 k120 ch3 d12 l14 ch1 r120 215 119 216 hinge 1 15 217 231 ch2 232 341 ch3 e12 357 m14 359 342 446 chs k2 del 447 119 447 221 215 disulfide with kappa light chain 1 215 v kappa homo sapiens igkv1 9 03 78 1 igkj1 01 100 cdr imgt 7 3 9 27 33 51 53 90 98 1 108 homo sapiens igkc 01 100 km3 a45 1 154 v101 192 109 215 dimer 227 227 230 230 bisdisulfide produced in chinese hamster ovary cho cells cell line cho dg44 glycoform alfa
  • Immunoglobulin G1 [de-448-lysine], anti-(human cytotoxic T-lymphocyte-associated protein 4) (human monoclonal BA3071 γ1-chain), disulfide with human monoclonal BA3071 κ-chain, dimer
  • immunoglobulin g1 de 448 lysine anti human cytotoxic t lymphocyte associated protein 4 human monoclonal ba3071 γ1 chain disulfide with human monoclonal ba3071 κ chain dimer
  • immunoglobulin g1 kappa anti homo sapiens ctla4 cytotoxic t lymphocyte associated protein 4 ctla 4 cd152 monoclonal antibody
  • Immunoglobulin G1-kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], monoclonal antibody

CAS registry numbers
  • 2460399-39-5
ChEMBL ID
CHEMBL5314830
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • ZT62XSC86F

First in class
No
Orphan designation
No

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
  • Condition identifier
    MONDO_0005070
  • Condition identifier
    MONDO_0005105
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005233
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0010150
    Highest recorded phase
    2

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Glycosylation sites (N)
    Sequence
    298 $ 298''
  • Component
    Heavy chain
    Type
    Protein
    Sequence
    EVQLVESGGGLVQPGGSLRISCAASGETESHYTMHWVRQAPGKGLEWVSFISYDGNNKYYADSVKGRETISRDNSKNTLYLQMNSLRAEDTAVYYCARTGWLGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
  • Component
    Disulfide bridges
    Sequence
    22-95 $ 22''-96'' $ 23'-89' $ 23'''-89''' $ 135'-195' $ 135'''-195''' $ 145-201 $ 145''-201'' $ 221-215' $ 221''-215''' $ 227-227'' $ 230-230'' $ 262-322 $ 262''-322'' $ 368-426 $ 368''-426''
  • Component
    Light chain
    Type
    Protein
    Sequence
    AIQLTQSPSSLSASVGDRVTITCRASQYVGSSYLAWYLQKPGQSPQLLIYGAFSRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQDGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Related records

Trials (2)

In development for (4)